Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

EPT Disclosure

6 Oct 2008 10:48

RNS Number : 1398F
Landsbanki Securities UK
06 October 2008
Β 

FORM 38.5(a)

Β 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERSΒ 

WITH RECOGNISED INTERMEDIARY STATUS

DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(a) of the Takeover Code)

1. KEY INFORMATION

Β 

Name of exempt principal trader

Landsbanki Securities (UK) Ltd

Company dealt in

Flying Brands

Class of relevant security to which the dealings being disclosed relateΒ (Note 1)

Units (1 Ord 1p & 1 Ord 0.005p)

Date of dealing

03 OctoberΒ 2008

Β 

Β 

2. DEALINGSΒ (Note 2)

Β 

(a) Purchases and sales

Β 

Total number of securities purchased

Highest price paid (Note 3)

Lowest price paid (Note 3)

Β 

Β 

Total number of securities sold

Highest price received (Note 3)

Lowest price received (Note 3)Β 

1694

45.20p sterling

45.20p sterling

Β 

(b) Derivatives transactions (other than options)

Β 

Product name,Β  e.g. CFD

Long/shortΒ (Note 4)

Number of securitiesΒ (Note 5)

Price per unitΒ (Note 3)

Β 

Β 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Β 

Product name,e.g call option

Writing,Β  selling,Β  purchasing, varying etc

Number of securities to which the option relatesΒ (Note 5)

Exercise priceΒ 

Type, e.g. American, European etc.

Expiry date

Option moneypaid/received per unitΒ (Note 3)

Β 

(ii) Exercising

Β 

Product name, e.g. call option

Number of securitiesΒ 

Exercise price per unitΒ (Note 3)

Β 

Β 

Β 

3. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Β 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

……………………………………………………………………

Β 

……………………………………………………………………

Β 

Β 

Β 

Date of disclosure

06 OctoberΒ 2008

Contact name

Jen Townshend

Telephone number

020 7426Β 9001

Name of offeree/offeror with which connected

Flying Brands

Nature of connection (Note 6)

Β Adviser &Β Β Broker

Β 

Β 

Notes

Β 

The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website atΒ www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
EMMUNSKRWWRRRRA
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.